



LKT Laboratories, Inc.

BYL719

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID B9700

CAS No. 1217486-61-7

Chemical Name

Synonym Alpelisib, NVP-BYL719, BYL-719

Formula $C_{19}H_{22}F_3N_5O_2S$

Formula Wt. 441.47

Melting Point

Purity $\geq 99\%$, $\geq 99\%ee$

Solubility DMSO 88 mg/mL (199.33 mM)

Ethanol 2 mg/mL (4.53 mM)


Water Insoluble

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description

BYL-719 is an ATP-competitive oral PI3K inhibitor selective for the p110 α isoform that is activated by a mutant PIK3CA gene in HER2+ breast cancers and gastric cancers. BYL-719 exhibits anticancer chemotherapeutic activity and inhibits proliferation in a variety of cell lines. IGF1 and neuregulin 1 activate mTOR, a downstream target of PI3K that mediates resistance to BYL-719 in some in vitro cancer models. This compound also decreases invasion and epithelial-to-mesenchymal transition (EMT) in cellular and animal models of squamous cell lung cancer.



Bulk quantities available upon request

Product ID	Size
B9700	1 mg
B9700	5 mg
B9700	25 mg
B9700	100 mg

References

Bonelli MA, Cavazzoni A, Sacconi F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. *Mol Cancer Ther.* 2015 May 26. [Epub ahead of print]. PMID: 26013318.

Elkabets M, Vora S, Juric D, et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 α Inhibitors in PIK3CA-Mutant Breast Cancer. *Sci Transl Med.* 2013 Jul 31;5(196):196ra99. PMID: 23903756.

Abstract: Juric. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. *American Association for Cancer Research.* 2012.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.